# A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies

> **NCT07316907** · PHASE1 · NOT_YET_RECRUITING · sponsor: **YANRU WANG** · enrollment: 12 (estimated)

## Conditions studied

- Hematologic Malignancies
- Lymphoma

## Interventions

- **BIOLOGICAL:** 19UCART injection

## Key facts

- **NCT ID:** NCT07316907
- **Lead sponsor:** YANRU WANG
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-22
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07316907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07316907, "A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07316907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*